V
Veerle Vanvoorden
Researcher at UCB
Publications - 8
Citations - 385
Veerle Vanvoorden is an academic researcher from UCB. The author has contributed to research in topics: Randomized controlled trial & Placebo-controlled study. The author has an hindex of 4, co-authored 7 publications receiving 90 citations.
Papers
More filters
Journal ArticleDOI
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Kristian Reich,Kim A. Papp,Andrew Blauvelt,Richard G. Langley,April W. Armstrong,Richard B. Warren,Kenneth B. Gordon,Joseph F. Merola,Yukari Okubo,Cynthia Madden,Maggie Wang,Christopher Cioffi,Veerle Vanvoorden,Mark Lebwohl +13 more
TL;DR: Bimekizumab was more efficacious than ustekinumab and placebo in the treatment of moderate to severe plaque psoriasis and the bimekzumab safety profile was consistent with that observed in previous studies.
Journal ArticleDOI
Bimekizumab versus Secukinumab in Plaque Psoriasis.
Kristian Reich,Richard B. Warren,Mark Lebwohl,Melinda Gooderham,Bruce Strober,Richard G. Langley,Carle Paul,Dirk De Cuyper,Veerle Vanvoorden,Cynthia Madden,Christopher Cioffi,Luke Peterson,Andrew Blauvelt +12 more
TL;DR: Bimekizumab as discussed by the authors is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleuxin 17F.
Journal ArticleDOI
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Kenneth B. Gordon,Peter Foley,James G. Krueger,Andreas Pinter,Kristian Reich,Ronald Vender,Veerle Vanvoorden,Cynthia Madden,Katy White,Christopher Cioffi,Andrew Blauvelt +10 more
TL;DR: The BE READY trial as discussed by the authors investigated the efficacy and safety of bimekizumab in patients with moderate to severe plaque psoriasis, the effects of treatment withdrawal, and two maintenance dosing schedules over 56 weeks.
Journal ArticleDOI
Bimekizumab versus Adalimumab in Plaque Psoriasis.
Richard B. Warren,Andrew Blauvelt,Jerry Bagel,Kim A. Papp,Paul S. Yamauchi,April W. Armstrong,Richard G. Langley,Veerle Vanvoorden,Dirk De Cuyper,Christopher Cioffi,Luke Peterson,Nancy Cross,Kristian Reich +12 more
TL;DR: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleuxin 17F as discussed by the authors.
Journal ArticleDOI
Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)
Richard B. Warren,Andrew Blauvelt,Jerry Bagel,Kim A. Papp,Paul S. Yamauchi,April W. Armstrong,Richard G. Langley,Veerle Vanvoorden,D. De Cuyper,Luke Peterson,Nancy Cross,Kristian Reich +11 more
TL;DR: In this paper, the authors propose a method to solve the problem of unstructured data. But it requires not available data sets, which is not available in this paper, and